Stemtech Corporation
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsStemtech Corp is a global network-marketing company selling stem cell nutrition and skincare products through independent distributors under brands including RCM System, stemrelease3, StemFlo, MigraStem and OraStem.
What they do
Stemtech develops science-based wellness products it describes as supporting healthy stem cell physiology, marketed as stem cell enhancers. Products are sold internationally by the company's subsidiaries and through independent distributors under the Stem Cell Nutrition Company brand. Brand lines include RCM System, stemrelease3, StemFlo, MigraStem and OraStem oral health care, plus skincare products Cellect One Rapid Renew stem cell peptide night cream and, added in January 2025, Cellect One Shield HOCL.
Revenue drivers
- Stem cell nutrition products — Core product family sold under RCM System, stemrelease3, StemFlo and MigraStem, marketed as stem cell enhancers and distributed internationally through independent distributors.
- OraStem oral health care — Oral health care line marketed under the OraStem brand within the company's stem cell nutrition portfolio.
- Cellect One skincare — Skincare products, including Cellect One Rapid Renew stem cell peptide night cream introduced in December 2022 and Cellect One Shield HOCL introduced in January 2025.
Recent performance
Annual revenue fell to $2.9M in 2025 from $5.1M in 2024, while net loss was $4.0M in 2025 versus $3.8M in 2024. Operating cash flow was negative $483,583 in 2025 and negative $601,198 in 2024, continuing a run of negative operating cash flow since at least 2021. Recent quarterly revenue was $852,300 for the quarter ended 2025-09-30, $458,109 for 2025-12-31, $462,957 for 2026-03-31 and $629,312 for 2026-06-30. At 2026-06-30 the company reported total assets of $3.2M, total liabilities of $11.1M, shareholder equity of negative $7.5M and cash of $246,772.
Strategy
Stemtech positions itself as a pioneer in stem cell science and markets its products internationally through subsidiary operations and independent distributors. The company has expanded its product line beyond stem cell nutrition into skincare, introducing Cellect One Rapid Renew in December 2022 and Cellect One Shield HOCL in January 2025. Filings describe strategic plans, financial performance, capital requirements and additional financing needs as factors affecting future results, but the provided excerpts do not quantify planned investments or specific growth targets.
Risks
- Negative equity and weak liquidity — At 2026-06-30 shareholder equity was negative $7.5M with only $246,772 of cash against $11.1M of total liabilities.
- Revenue decline — Annual revenue dropped to $2.9M in 2025 from $5.1M in 2024, and quarterly revenue has ranged between roughly $458,000 and $852,000 in recent periods.
- Persistent losses and cash burn — The company reported net losses every year from 2021 through 2025 and negative operating cash flow in each of those years.
- Financing dependence — The company discloses estimates of capital requirements and needs for additional financing as a risk factor, and the 10-Q notes it remains an emerging growth company.
Outlook
Management's forward-looking discussion cites strategic plans, financial performance, capital requirements and needs for additional financing as key uncertainties, without providing specific revenue or earnings guidance in the excerpts. The company reported no unresolved staff comments. The provided filings do not include quantified projections or committed financing arrangements.